Your browser doesn't support javascript.
loading
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
Weidenbacher, Payton A-B; Sanyal, Mrinmoy; Friedland, Natalia; Tang, Shaogeng; Arunachalam, Prabhu S; Hu, Mengyun; Kumru, Ozan S; Morris, Mary Kate; Fontenot, Jane; Shirreff, Lisa; Do, Jonathan; Cheng, Ya-Chen; Vasudevan, Gayathri; Feinberg, Mark B; Villinger, Francois J; Hanson, Carl; Joshi, Sangeeta B; Volkin, David B; Pulendran, Bali; Kim, Peter S.
Afiliação
  • Weidenbacher PA; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Sanyal M; Department of Chemistry, Stanford University, Stanford, CA, USA.
  • Friedland N; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Tang S; Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Arunachalam PS; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Hu M; Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Kumru OS; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Morris MK; Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Fontenot J; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
  • Shirreff L; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
  • Do J; Vaccine Analytics and Formulation Center, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.
  • Cheng YC; California Department of Public Health, Richmond, CA, USA.
  • Vasudevan G; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Feinberg MB; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Villinger FJ; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Hanson C; Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Joshi SB; Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
  • Volkin DB; Department of Biochemistry, School of Medicine, Stanford University, Stanford, CA, USA.
  • Pulendran B; IAVI, New York, NY, USA.
  • Kim PS; IAVI, New York, NY, USA.
bioRxiv ; 2022 Dec 26.
Article em En | MEDLINE | ID: mdl-36597527
ABSTRACT
While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ∻one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly booster vaccine, and as a primary vaccine for pediatric use including in infants.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: BioRxiv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos